RecruitingPhase 1NCT07181369

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Studying Familial cold urticaria

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Granular Therapeutics Limited
Intervention: GTX-B001(drug)
Enrollment: 72 target
Eligibility: 18-75 years · All sexes
Timeline: 2025 – 2027

Study locations (2)

Charité Research Organization gmbh, Berlin, Germany
Fraunhofer Institute For Translational Medicine And Pharmacology, Berlin, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07181369 on ClinicalTrials.gov

Other trials for Familial cold urticaria

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT07266402
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Celldex Therapeutics

See all trials for Familial cold urticaria →

← Back to all trials